For Type 2 diabetics, platelet activation plays a key role in atherothrombosis (the leading cause of mortality in the Western world). These individuals are at higher risk for cardiovascular-related deaths from both strokes and heart attacks. The high levels of blood sugars can cause platelet aggregation and blood hyperviscosity. In this study, researchers monitored platelet aggregation during a 5 day course of hyperbaric therapy (HBOT) at 2.4 ATA and observed a significant reduction in platelet aggregation parameters. This study demonstrates that HBOT could provide diabetics another protective mechanism, as this procedure has already been shown to help sensitize insulin levels and effectively help lower blood sugar levels. Both of these mechanisms can be extremely important in helping diabetics reduce their overall cardiovascular risks and helping them to live  longer, while reducing their chance of living in a  debilitated state from some of the devastating complication of diabetes (for example strokes and heart attacks). <view study> Read Less

Pulmonary fibrosis is a chronic progressive lung disease that is becoming more prevalent and poses medical challenges due to the limited therapeutic options available. The rise in the aging process along with the rise in pulmonary complications from long COVID has led to new research studies to help identify potential treatment options. Hyperbaric oxygen therapy (HBOT) is emerging as one of them, showing good promise with clinical outcome measures. To demonstrate HBOT's influence on this disease, researchers in this study first exposed a group of rats to bleomycin (a chemotherapeutic agent that is known to cause acute pulmonary toxicity) directly into the trahea. This is to induce pulmonary fibrosis. They waited 7 days and then treated the rats with 14 days of HBOT at 2.5 ATA  for 90 minutes. The rats that were treated with this 2 week course of HBOT demonstrated a marked reduction in TGF-β, which is normally elevated and plays an active role in the development of the fibrosis.  The findings in this study support the use of HBOT as a potential "life changing" therapy for patients with pulmonary fibrosis <view study> Read Less

The emergence of cancer immunotherapy has already shown some remarkable results for the treatment of solid tumors. As good as this is, patients seem to lack the ability to respond to immune checkpoint inhibitors, thus demonstrating a primary resistance to immunotherapy. By reducing tumor hypoxia (low oxygen) within solid tumors. hyperbaric oxygen therapy (HBOT) can help reinvigorate anti-cancer immunity. In this study, HBOT was able to stimulate a suppressed immune system and help PD-1 Ab trigger robust cytotoxic T lymphocytes and long-lasting immunological memory to inhibit tumor relapses. Emerging research suggests that T cell-directed checkpoint antibodies such as anti-programmed cell death protein-1 (PD-1) or programmed death-ligand-1 (PD-L1) can impact innate immunity by both direct and indirect pathways, which may ultimately shape clinical efficacy. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.. Hyperbaric Oxygen Boosts PD-1 Antibody Delivery -- "The results illustrate that HBO bolsters antitumor efficacy of PD-1 Ab, and the HBO-PD-1 Ab combination is a promising stroma-rich solid tumors' treatment in the clinic" <view study> Read Less

Intermittent hyperbaric oxygen therapy is shown to help reduce the cellular and biological aging of the body and effectively help us live longer and more important, healthier. One of the effects seen during the aging process is a decline in cerebral blood flow, causing a reduction in brain oxygen levels. Cognitive and mental performance are effected, particularly in attention and information processing speed. Hyperbaric oxygen therapy can help combat the decline in cognitive function by supplying the brain with a surplus of oxygen. In addition, the intermittent application of this procedure causes changes in oxygen tensions that promote promote beneficial regulatory protein changes (from the flux in oxygen levels from high to normal). These changes include an increase in SIRT1, HIF-1A, and a reduction in CD28^null senescent T helper and cytotoxic T cells.

• SIRT1 increases mitochondrial biogenesis (energy production) and attenuates telomere length thereby contributing to increased healthy life-span and reducing aging-related diseases.
• CD28^null senescent T helper and cytotoxic T cells are aging-associated biomarkers and lower levels are associated with reduction in aging
• HIF-1A  functions as a master regulator of cellular and systemic homeostatic response to hypoxia (low oxygen) by activating transcription of many genes, including those involved in energy metabolism, angiogenesis (creation of new blood vessels and circulation) and much more

As you can see, hyperbaric oxygen therapy produces numerous benefits for helping to counteract the negative effects seen from the aging process <view study> Read Less

Obesity and diabetes are both prevalent and rapidly increasing in the aging population, leading to impairment in cardiac function. In this study, rats were given a chemical compound (D-Galactose) to accelerate the aging process and produce cardiac dysfunction. The rats were pre-diabetic and  were given hyperbaric oxygen therapy 60 minutes 2.0 ATA daily. With the addition of hyperbaric therapy, the rats were able to show improvements in cardiac function, along with many other benefits. Here are the authors' conclusions for this study: "Our results indicated that hyperbaric oxygen therapy (HBOT) could restore the normal cardiac function in either aging induced by D-gal rats or high-fat diet induced pre-diabetic rats. Mechanistically, HBOT effectively alleviated the cardiac dysfunction in aging pre-diabetic rats through decreased oxidative stress, inflammation, apoptosis, dysfunctional mitochondria, metabolic and autophagic impairments. Thus, HBOT could be a potential therapeutic intervention in aging pre-diabetic people with impaired cardiac function" <view study> Read Less